Is the Demonstration of Adenoma Reduction With Rofecoxib a Pyrrhic Victory?
- 31 December 2006
- journal article
- editorial
- Published by Elsevier in Gastroenterology
- Vol. 131 (6) , 2003-2005
- https://doi.org/10.1053/j.gastro.2006.10.052
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- A Randomized Trial of Rofecoxib for the Chemoprevention of Colorectal AdenomasGastroenterology, 2006
- Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia EventsJAMA, 2006
- Cardiovascular Risk and Inhibition of CyclooxygenaseJAMA, 2006
- Risks and Benefits of Celecoxib to Prevent Recurrent AdenomasNew England Journal of Medicine, 2006
- Celecoxib for the Prevention of Colorectal Adenomatous PolypsNew England Journal of Medicine, 2006
- Celecoxib for the Prevention of Sporadic Colorectal AdenomasNew England Journal of Medicine, 2006
- Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trialsBMJ, 2006
- Low-Dose Aspirin in the Primary Prevention of CancerJAMA, 2005
- A Prospective Study of Aspirin Use and the Risk for Colorectal AdenomaAnnals of Internal Medicine, 2004
- Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health ProfessionalsAnnals of Internal Medicine, 1994